Flexion Therapeutics

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.
We embrace a philosophy of scientific entrepreneurship which spurs innovation and empowers and inspires our people to discover, develop and commercialize transformative therapies which can make a meaningful difference in the lives of patients.
The Flexion Medical Affairs team is dedicated to identifying, generating, communicating and gathering scientific knowledge of musculoskeletal conditions as trusted scientific colleagues and strategic business partners, ultimately improving the management of patients with these conditions.

Flexion offers a two year post-PharmD fellowship in Medical Affairs.

LEARN ABOUT FLEXION
FLEXION FELLOWSHIP BROCHURE

New partnership under development for the 2020-22 cycle.

IPSEN

Ipsen Biopharmaceuticals, Inc. is launching a 2-year post-PharmD fellowship in U.S. Medical Affairs in collaboration with Northeastern University, School of Pharmacy.
Ipsen is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Our presence in North America dates back to 1976, and now includes Ipsen’s third global hub right in the heart of the leading global biotech ecosystem in Cambridge, Mass., where a fully integrated biopharmaceutical team across External Innovation and Partnering, R&D, Manufacturing and Commercial operations collaborates. With Ipsen’s expansion of its footprint in Cambridge, and new North America headquarters in Kendall Square, the group is building a sustainable innovation engine within the biotech community.

IPSEN offers two year post-PharmD fellowships in Medical Affairs.

LEARN ABOUT IPSEN IPSEN FELLOWSHIP BROCHURE

New partnership under development for the 2020-22 cycle.

Verastem Oncology

Verastem Oncology™ is a biopharmaceutical company focused on developing therapies to improve the lives of patients diagnosed with cancer in ways that are truly meaningful to them. When it comes to combating cancer, we realize there are no “one size fits all” treatment approaches. We understand that every cancer lives in an intricate and complex micro-environment, creating significant unmet needs which must be addressed. It’s why we remain open to new ideas and selectively pursue science with the potential to make a significant impact for physicians, patients and their caregivers. Verastem Oncology™ has assembled a team of passionate leaders from the biopharmaceutical industry, bringing together their experiences of drug discovery, drug development and commercialization. With deep expertise, agility and purpose, we are identifying and advancing late-stage, first-in-class clinical assets to market.

Verastem Oncology™ offers 2-year post-Pharm.D. fellowships in Medical Affairs, Regulatory Affairs and Safety & Pharmcovigilence in collaboration with Northeastern University, School of Pharmacy.

2020-22 Fellowship Positions: Not recruiting for this cycle.

LEARN ABOUT VERASTEM

Wave Life Sciences

Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Using PRISM, our proprietary discovery and drug development platform that enables the precise design, optimization and production of novel stereopure oligonucleotides, we aspire to develop best in class medicines across multiple therapeutic modalities. Our goal is to develop and commercialize disease-modifying medicines for genetically defined diseases with a high degree of unmet medical need. Our initial focus for our clinical development programs is in neurology. We are conducting clinical trials of our lead program in Duchenne muscular dystrophy (“DMD”) targeting exon 51 and our two lead programs in Huntington’s disease (“HD”). We are advancing three additional development programs, targeting exon 53 in DMD and C9ORF72 in amyotrophic lateral sclerosis and frontotemporal dementia.

LEARN ABOUT WAVE LIFE SCIENCES
WAVE LIFE SCIENCES BROCHURE

New partnership under development.

Critical Care Fellowship

With the rich biopharmaceutical and advanced clinical practice landscape of greater Boston and Cambridge, MA as a backdrop, our fellowships offer students the opportunity to work with innovative industry and health system partners in a variety of specialty areas, while partnering with Northeastern University faculty in the areas of research, scholarship, and teaching.